A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2014
At a glance
- Drugs Ranolazine (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Jun 2017 Biomarkers information updated
- 28 Jan 2014 Planned number of patients changed from 420 to 400 according to European Clinical Trials Database record.
- 12 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.